Attesting to human relevance, patients treated with 4-6 months neoadjuvant hormone therapy21 exhibit high expression of ASCL1 when compared to the treatment naïve group (Fig. 2f), which correlated with high expression of SYP (Supplementary Fig. 2i) supporting our in vitro data that ASCL1 upregulation is an early event following suppression of AR signaling in prostate cancer. The gene discussed is ASCL1; the disease is Familial prostate cancer.